After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.

Of the big oncology deals since 2016, there are still plenty that could go either way.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.

Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.